| Loss Per Common Share |
4. Loss Per Common Share Diluted loss per common share is the same as basic loss per common share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company’s net loss. The following common share equivalent securities have been excluded from the calculation of weighted average common shares outstanding because the effect is anti-dilutive for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
Anti-Dilutive Common Share Equivalents |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Stock options |
|
|
8,252,768 |
|
|
|
7,306,429 |
|
|
|
8,252,768 |
|
|
|
7,306,429 |
|
Restricted stock units |
|
|
10,114,472 |
|
|
|
7,969,477 |
|
|
|
10,114,472 |
|
|
|
7,969,477 |
|
Employee stock purchase plan |
|
|
168,002 |
|
|
|
135,553 |
|
|
|
168,002 |
|
|
|
135,553 |
|
Total anti-dilutive common share equivalents |
|
|
18,535,242 |
|
|
|
15,411,459 |
|
|
|
18,535,242 |
|
|
|
15,411,459 |
|
Basic and diluted net loss per common share is calculated as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(8,091 |
) |
|
$ |
(25,371 |
) |
|
$ |
(42,852 |
) |
|
$ |
(76,255 |
) |
Net loss attributable to common stockholders |
|
$ |
(8,091 |
) |
|
$ |
(25,371 |
) |
|
$ |
(42,852 |
) |
|
$ |
(76,255 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding, basic and diluted |
|
|
202,526,844 |
|
|
|
198,234,392 |
|
|
|
201,338,550 |
|
|
|
197,710,104 |
|
Net loss per common share, basic and diluted |
|
$ |
(0.04 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.39 |
) |
|